S2Medical AB (publ)
STO:S2M
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
S2Medical AB (publ)
Revenue
S2Medical AB (publ)
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
S2Medical AB (publ)
STO:S2M
|
Revenue
kr14.4m
|
CAGR 3-Years
45%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
O
|
OssDsign AB
STO:OSSD
|
Revenue
kr180.2m
|
CAGR 3-Years
47%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
Xvivo Perfusion AB
STO:XVIVO
|
Revenue
kr812.2m
|
CAGR 3-Years
25%
|
CAGR 5-Years
35%
|
CAGR 10-Years
21%
|
|
|
D
|
Doxa AB
STO:DOXA
|
Revenue
kr20.3m
|
CAGR 3-Years
57%
|
CAGR 5-Years
19%
|
CAGR 10-Years
3%
|
|
|
Bactiguard Holding AB
STO:BACTI B
|
Revenue
kr215.9m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
V
|
Vimian Group AB
STO:VIMIAN
|
Revenue
€425m
|
CAGR 3-Years
15%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
S2Medical AB (publ)
Glance View
S2Medical AB engages in research and development in biotechnology. The company is headquartered in Linkoping, Ostergotland. The company went IPO on 2018-11-28. The firm focuses on developing products for healing burns and chronic wounds, from debridement and granulation to reepithelialization. The firm's product portfolio includes INSTAQRETT, a sterile single-use mechanical debridement tool, the Epiprotect product line based on its collagen-mimicking Eiratex material, which includes EPIPROTECT Safestop, a blood-stilling membrane dressing, EPIPROTECT 2117, a synthetic substitute to allografts and xenografts, EPIPROTECT ULCER, dressing for treating ulcers, as well as INSTABIND bandages and Instagraft, a single-use medical device designed to treat chronic wounds with microtransplants from the patient's own skin without creating any new wounds. The firm is also the official distributor of Silverlon antimicrobial dressings for Nordic countries. In addition, it operates the S2Clinic, a wound healing center in Sweden.
See Also
What is S2Medical AB (publ)'s Revenue?
Revenue
14.4m
SEK
Based on the financial report for Dec 31, 2025, S2Medical AB (publ)'s Revenue amounts to 14.4m SEK.
What is S2Medical AB (publ)'s Revenue growth rate?
Revenue CAGR 5Y
-11%
Over the last year, the Revenue growth was -2%. The average annual Revenue growth rates for S2Medical AB (publ) have been 45% over the past three years , -11% over the past five years .
